SCHEMBL4831425

SCHEMBL4831425

Cc1ccc(N)cc1NC(=O)c1cccc(N2CCN(C)CC2)c1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.53
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
GAA P10253 2/20 0.53
ALDH1A1 P00352 2/20 0.53
WDR5 P61964 7/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
ATM Q13315 1/20 0.47
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 2/20 0.47
POLB P06746 1/20 0.46
RBBP5 Q15291 1/20 0.46
ASH2L Q9UBL3 1/20 0.46
MAPT P10636 2/20 0.45
KDM4E B2RXH2 2/20 0.45
BRPF1 P55201 1/20 0.44
MAPK10 P53779 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RAD52 P43351 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1140070 0.84 MAPK14 (0.54) WDR5
SCHEMBL4829614 0.79 HDAC3 (0.48) MAPK1KMT2AMEN1GAAALDH1A1
SCHEMBL6979224 0.76 MAPK14 (0.62)
SCHEMBL4831385 0.75 MEN1 (0.47) MAPK1KMT2AMEN1GAAALDH1A1
SCHEMBL4831705 0.74 HPGDS (0.56) WDR5POLB
SCHEMBL4823504 0.74 WDR5 (0.68) KMT2AMEN1GAAALDH1A1WDR5
SCHEMBL3434271 0.74 KDM4E (0.52) MAPK1KMT2AMEN1ALDH1A1NPSR1
SCHEMBL1140273 0.73 MAPK11 (0.54)
SCHEMBL4828091 0.72 HPGDS (0.59)
SCHEMBL6777439 0.72 BRPF1 (0.59) MAPK1KMT2AMEN1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442704-B2 Amide derivatives ASTRAZENECA AB (SE) 2008-10-28 US disclosed
US-7332483-B2 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease ASTRAZENECA AB (SE) 2008-02-19 US disclosed
US-20060281734-A1 Amide derivatives BROWN DEARG S 2006-12-14 US disclosed
US-7008945-B1 Amide derivatives ASTRAZENECA AB (SE) 2006-03-07 US disclosed
US-20050245551-A1 Amide derivatives ASTRAZENECA AB 2005-11-03 US disclosed
CN-1178932-C Amide derivatives 2004-12-08 CN disclosed
CN-1350530-A Amide derivatives ASTRAZENECA AB (SE) 2002-05-22 CN disclosed
EP-1163237-A1 AMIDE DERIVATIVES AstraZeneca AB (SE) 2001-12-19 EP disclosed
WO-2000055153-A1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245551-A1 Amide derivatives IL6, IL6ST, IL1B MAPK1 1663/4885KMT2A 2740/4885MEN1 2386/4885
US-20060281734-A1 Amide derivatives IL6, IL6ST, IL1B MAPK1 1663/4885KMT2A 2740/4885MEN1 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.